March 27, 2025
Hamburg-Based Life Sciences Startup mo:re Secures €2.3M in Seed Funding & Unveils Lab Platform to Advance Animal-Free Drug Development
Hamburg, Germany –
mo:re GmbH, a company specializing in automating the planning, cultivation, and analysis of complex 3D cell culture models, has raised €2.3 million in a seed funding round announced on March 26, 2025. The investment, led by High-Tech Gründerfonds (HTGF), also includes contributions from IFB Innovationsstarter GmbH, Gilson, NEDGEX, Nidobirds Ventures, and private investors R&R Medical and Martin Blüggel. The funding will support the further development of organ models, and commercial expansion. In addition, mo:re officially unveiled its first product at SLAS 2025 in San Diego, marking a significant step forward in advancing its automated 3D cell culture platform.
About mo:re
Founded in 2021 by David Hackenberger and Lukas Gaats, mo:re offers an innovative robotic and software platform designed to simplify and standardize cell culture studies. By automating long-term investigations and integrating AI-assisted cultivation methods, the company ensures enhanced traceability, reproducibility, and reliability for research publications and regulatory approval processes.
Purpose of financing
With the newly secured funds, mo:re plans to accelerate the commercial launch of its first automated 3D cell culture product. The company aims to expand its research capabilities, refine its organ models, and strengthen its position in the life sciences sector. Additionally, the funding will support team growth and operational scaling across key markets.
CEO’s Insights
Lukas Gaats, CEO of mo:re, highlighted the significance of the investment:
"With this funding, we aim to establish our presence in the market and continue building our team. Our focus is on developing further scientific applications to unlock the full potential of our platform in collaboration with our customers and internal R&D lab."
Investor Perspective
Dr. Christian Kannemeier, Senior Investment Manager at HTGF, expressed confidence in the company's trajectory:
"mo:re is poised to transform 3D cell culture by providing researchers with easy access to standardized and reproducible methodologies. Their innovative approach will significantly enhance laboratory automation and drug discovery."
Stefanie Höhn, Senior Investment Manager at IFB, added:
“Our investment in mo:re reflects confidence in their vision. Their platform has the potential to redefine non-animal testing methods in life sciences.”
Conclusion
mo:re’s fully integrated system sets it apart by eliminating inconsistencies in 3D cell culture. With its first product now on the market, the company is positioned for rapid growth, targeting expansion in Europe and the U.S. to drive next-gen laboratory automation and drug discovery innovation.
For updates, visit mo:re on LinkedIn.